- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05706701
Nicotine Flux, a Potentially Powerful Tool for Regulating Nicotine Delivery From Electronic Cigarettes
Study Overview
Status
Conditions
Detailed Description
The purpose of this study is to examine the influence of nicotine flux, and nicotine form, on the rate and dose of nicotine delivery obtained from arterial blood measurements. This study involves a 4 x 2 crossover experimental design of four nicotine fluxes: 9, 18, 27, 35 μg/sec, and two nicotine forms (i.e., free-base and protonated). These nicotine fluxes are within the range reported for ENDS (3.1-111µg/sec). The investigators will isolate the effect of form on the pharmacokinetics of nicotine delivery by controlling for puffing behavior. The investigators will hold puff topography constant by controlling puff duration, inter-puff interval, and number of puffs using the LabVape PTL and confirm the data using eTop.
The flux/form conditions will be tested by participants in two lab visits separated by three weeks to minimize carryover effects. All sessions will be double-blinded. In the first visit, participants will use the ENDS device with one nicotine form and four fluxes in random order. Participants will be instructed to attend the lab for a second visit, to test the four fluxes but with the other nicotine form. The second visit will allow us to isolate the effect of nicotine form on nicotine delivery. The order of nicotine form in the two visits will be counter-balanced across participants. Outcome measures include arterial blood nicotine delivery, and puff topography.
Participants will be instructed to use the Subox mini C ENDS device connected to the LabVape PTL (which limits puff duration to 3 seconds) in four bouts separated by a 60min resting period. The e-liquids vaped are as follows: Propylene glycol(PG)/Glycerol (VG), 30/70 ratio by volume. Nicotine at different concentrations: (2, 4, 7 and 10mg/mL) Benzoic acid: approximately 1:1 molar ratio with nicotine. All these ingredients will be used to prepare the needed e-liquids to conduct the study.
All bouts will be directed; each bout will consist of 3 puffs in which puff duration is fixed to 3sec, as in 50, and inter-puff interval fixed to 30sec (CORESTA recommended method Nº 81).123 The puff duration and inter-puff interval will be fixed using the LabVape PTL. A puff topography device (eTop) will record the puffing topography to identify any deviation between directed and actual puffs drawn and to measure the puffing flow rate. Participants will be trained to follow the puffing cues prior to sampling using an unpowered ENDS device. For arterial blood sampling, a radial arterial line will be placed on the non-dominant side to provide access to blood samples during vaping sessions. Each blood sample (0.5cc) will be drawn manually by a trained nurse at every time point and stored in the freezer at -25°C. Blood nicotine samples will be assayed using LCMS/ MS with deuterated internal standards, as in 114. Blood will be sampled 30sec prior to the initial puff, 5, 15, and 25sec after each puff, and 60sec after the last puff of a bout. The obtained data will be used to calculate pharmacokinetic parameters of nicotine delivery under each condition (Cmax, Tmax, dCi/dt, and AUC). AUC from 0 to 160min for the four 3-puff directed bouts will be estimated using a non-compartmental model and trapezoidal rule. All measures will be corrected for baseline values by subtracting the blood nicotine concentrations by the initial value (at the start of each bout).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stylianos C Mysirlidis, B.S.
- Phone Number: 203-824-9215
- Email: vape.study@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Human Research Unit (HRU)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Above 21 years of age
- Use ENDS at least 3 months and at least 3 times a week.
- Be willing to provide informed consent, attend the lab, and abstain from tobacco/nicotine as required.
- Have a normal Allen test
Exclusion Criteria:
- Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, or hepatic pathology that would increase risk or would interfere with/mimic tobacco abstinence
- Untreated, unresolved active pulmonary or cardiovascular conditions (i.e. chest pain, dyspnea, acute infection, recurring bronchitis, and reactive airway disorder)
- Breast-feeding or Pregnant (by urinalysis at screening).
- Vaping less than 3 months and less than 3 times per week
- Taking anticoagulants and blood thinners
- Known hypersensitivity to propylene glycol
- History of environmental - bronchospastic allergies, multiple chemical sensitivities, or other airway sensitivities that require the use of an epi pen or that in the investigator's view would make it risky for participation.
- Has current symptoms as identified by the Health Assessment Checklist including cough, shortness of breath, chest pain, nausea, vomiting, stomach pain, diarrhea, fever, chills, or weight loss
- Participants intending to quit tobacco/nicotine use in the next 30 days will be excluded and referred to cessation treatment.
- Abnormal Allen Test (impaired collateral circulation)
- Positive pregnancy test at any study visit
- Infection of skin or soft tissue at insertion site (erythema, swelling, ulceration)
- Peripheral vascular disease
- Coronary artery disease/advance atherosclerosis
- Raynaud's phenomenon
- Coagulopathy (hereditary bleeding disorders, advanced liver disease)
- Thromboangiitis obliterans
- COPD/emphysema/chronic bronchitis
- Allergy to lidocaine or anesthetics
- Inability to tolerate blood draws for any reason
Additional Screening Procedures: Significant changes and/or abnormalities in these assessments during the study period may warrant exclusion at the discretion of the PI.
- Participants will be asked to answer the 4-item Patient-Reported Outcomes Measurement Information System (PROMIS) physical function scale and will be excluded if they report greater than "without any difficulty" on any single item as a screening tool
- Spirometry (baseline and before each visit)
- Physical Exam
- Application of the self-reported signs and symptoms health questionnaire with exclusion of those with chronic symptoms that would interfere with monitoring of vaping complications (baseline and * before each visit). Participants will be excluded and referred for medical treatment if they indicate dyspnea or cough symptoms are "severe."
- PROMIS Dyspnea Severity Item Pool
- PROMIS Dyspnea Characteristics
- PROMIS Fatigue Short Form
- Functional Assessment of Chronic Illness Therapy (FACIT) Cough item
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nicotine vaping group visit 1
Subjects will receive the either free-base or protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at their first of two visits.
In the first visit, participants will use the ENDS device with one nicotine form and four fluxes in random order.
Participants will be instructed to attend the lab for a second visit, to test the four fluxes but with the other nicotine form.
|
Participants will receive the free-base form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at one of their two visits.
Participants will use the ENDS device with free-base nicotine and four fluxes in random order.
Participants who received free-base nicotine during visit 1 will now receive protonated nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
|
Experimental: Nicotine vaping group visit 2
The same subjects from visit 1 will receive the either free-base or protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at their second study visit, using the opposite nicotine form that was used during the first visit.
|
Participants will receive the protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at the other study visit.
Participants will use the ENDS device with protonated nicotine and four fluxes in random order.
Participants who received protonated nicotine during visit 1 will now receive free-base nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Maximum Arterial Blood Nicotine Delivery (Cmax)
Time Frame: Day 1 and Week 3
|
For arterial blood sampling, a radial arterial line will be placed on the non-dominant side to provide access to blood samples during vaping sessions.
Blood will be sampled 30sec prior to the initial puff, 5, 15, and 25sec after each puff, and 60sec after the last puff of a bout (3 puffs per bout; 4 bouts per visit day; two visit days, separated by three weeks).
The obtained data will be used to calculate pharmacokinetic parameters of nicotine delivery under each condition.
|
Day 1 and Week 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Area Under the Curve for Nicotine (AUC)
Time Frame: Day 1 and Week 3
|
AUC from 0 to 160min for the four 3-puff directed bouts will be estimated using a non-compartmental model and trapezoidal rule. The four 3-puff directed bouts occur on both visit day 1 and 2, separated by 3 weeks. All measures will be corrected for baseline values by subtracting the blood nicotine concentrations by the initial value (at the start of each bout). |
Day 1 and Week 3
|
Change in Liquid Consumed
Time Frame: Day 1 and Week 3
|
Determined by ENDS gravimetric weight change.
Pre- and Post- vaping on both visit day 1 and 2, separated by 3 weeks.
|
Day 1 and Week 3
|
Change in Puff Topography
Time Frame: Day 1 and Week 3
|
Puff duration in seconds.
Measured after each puff (12 total per visit) on both visit day 1 and 2, separated by 3 weeks
|
Day 1 and Week 3
|
Change in Rate of Nicotine Rise after the Initial Puff (dCi/dt)
Time Frame: Day 1 and Week 3
|
Blood will be sampled 30sec prior to the initial puff, 5, 15, and 25sec after each puff, and 60sec after the last puff of a bout. Measurements occur 4 times per visit day, on both visit day 1 and 2, separated by 3 weeks). The obtained data will be used to calculate pharmacokinetic parameters of nicotine delivery under each condition (Cmax, Tmax, dCi/dt, and AUC). |
Day 1 and Week 3
|
Change in Time to Maximum Arterial Blood Level Nicotine Concentration (Tmax)
Time Frame: Day 1 and Week 3
|
Blood will be sampled 30sec prior to the initial puff, 5, 15, and 25sec after each puff, and 60sec after the last puff of a bout.
Measurements occur 4 times per visit day, on both visit day 1 and 2, separated by 3 weeks).
The obtained data will be used to calculate pharmacokinetic parameters of nicotine delivery under each condition (Cmax, Tmax, dCi/dt, and AUC).
|
Day 1 and Week 3
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen R Baldassarri, M.D., Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000031973
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nicotine Vaping
-
Philip Morris Products S.A.CompletedNicotine | Nicotine Vaping | VapingUnited Kingdom
-
Philip Morris Products S.A.CompletedNicotine | Nicotine Vaping | VapingUnited States
-
Philip Morris Products S.A.CompletedVaping | Nicotine AbsorptionUnited States
-
Virginia Polytechnic Institute and State UniversityMedical University of South CarolinaRecruitingCigarette Smoking | Nicotine VapingUnited States
-
Virginia Polytechnic Institute and State UniversityMedical University of South Carolina; National Cancer Institute (NCI)CompletedCigarette Smoking | Nicotine VapingUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingNicotine | Nicotine Vaping | E-cigarette UseUnited States
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA)Active, not recruitingNicotine Dependence | Nicotine Use Disorder | Nicotine Vaping | Vaping | Nicotine AddictionUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA)CompletedTobacco Smoking | Vaping | Nicotine Administration & Dosage | E-cigarettes | E-LiquidUnited States
-
American University of Beirut Medical CenterNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)RecruitingNicotine Dependence | Nicotine Vaping | Nicotine AddictionLebanon
-
Washington University School of MedicineNational Institute on Drug Abuse (NIDA); The University of Texas Health Science... and other collaboratorsNot yet recruitingNicotine Use Disorder | Nicotine Vaping
Clinical Trials on Nicotine vaping visit 1 (free-base nicotine)
-
Medical University of South CarolinaCompleted
-
Virginia Polytechnic Institute and State UniversityMedical University of South Carolina; National Cancer Institute (NCI)CompletedCigarette Smoking | Nicotine VapingUnited States
-
University of California, Los AngelesTobacco Related Disease Research ProgramCompleted
-
Universita degli Studi di CataniaLaboratory for Health Protection ResearchCompletedTobacco Abuse SmokeItaly
-
Universita degli Studi di CataniaCompleted
-
Ohio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA)Not yet recruitingCigarette Smoking-Related CarcinomaUnited States
-
National Institute on Drug Abuse (NIDA)National Cancer Institute (NCI)CompletedTobacco DependenceUnited States
-
Universita degli Studi di CataniaLega Italiana Anti FumoNot yet recruiting
-
Universita degli Studi di CataniaNot yet recruitingTobacco Smoking in Schizophrenic Patients
-
University Hospital MuensterUnknownSmoking | Nicotine Dependence | VapingGermany